Charlene S Dezzutti1,2, Sarah Yandura3, Lin Wang3, Bernard Moncla4,3, Elizabeth A Teeple5, Brid Devlin6, Jeremy Nuttall6, Elizabeth R Brown5, Lisa C Rohan4,3. 1. University of Pittsburgh, 204 Craft Avenue, Pittsburgh, Pennsylvania, 15213, USA. cdezzutti@mwri.magee.edu. 2. Magee-Womens Research Institute, Pittsburgh, Pennsylvania, USA. cdezzutti@mwri.magee.edu. 3. Magee-Womens Research Institute, Pittsburgh, Pennsylvania, USA. 4. University of Pittsburgh, 204 Craft Avenue, Pittsburgh, Pennsylvania, 15213, USA. 5. Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA. 6. International Partnership for Microbicides, Silver Springs, Maryland, USA.
Abstract
PURPOSE: Dapivirine (DPV), a non-nucleoside reverse transcriptase inhibitor, and maraviroc (MVC), a CCR5 antagonist, were formulated into aqueous gels designed to prevent mucosal HIV transmission. METHODS: 0.05% DPV, 0.1% MVC, 0.05% DPV/0.1% MVC and placebo gels were evaluated for pH, viscosity, osmolality, and in vitro release. In vitro assays and mucosal tissues were used to evaluate anti-HIV activity. Viability (Lactobacilli only) and epithelial integrity in cell lines and mucosal tissues defined safety. RESULTS: The gels were acidic and viscous. DPV gel had an osmolality of 893 mOsm/kg while the other gels had an osmolality of <100 mOsm/kg. MVC release was similar from the single and combination gels (~5 μg/cm(2)/min(1/2)), while DPV release was 10-fold less from the single as compared to the combination gel (0.4331 μg/cm(2)/min(1/2)). Titrations of the gels showed 10-fold more drug was needed to protect ectocervical than colonic tissue. The combination gel showed ~10- and 100-fold improved activity as compared to DPV and MVC gel, respectively. All gels were safe. CONCLUSIONS: The DPV/MVC gel showed a benefit blocking HIV infection of mucosal tissue compared to the single entity gels. Combination products with drugs affecting unique steps in the viral replication cycle would be advantageous for HIV prevention.
PURPOSE:Dapivirine (DPV), a non-nucleoside reverse transcriptase inhibitor, and maraviroc (MVC), a CCR5 antagonist, were formulated into aqueous gels designed to prevent mucosal HIV transmission. METHODS: 0.05% DPV, 0.1% MVC, 0.05% DPV/0.1% MVC and placebo gels were evaluated for pH, viscosity, osmolality, and in vitro release. In vitro assays and mucosal tissues were used to evaluate anti-HIV activity. Viability (Lactobacilli only) and epithelial integrity in cell lines and mucosal tissues defined safety. RESULTS: The gels were acidic and viscous. DPV gel had an osmolality of 893 mOsm/kg while the other gels had an osmolality of <100 mOsm/kg. MVC release was similar from the single and combination gels (~5 μg/cm(2)/min(1/2)), while DPV release was 10-fold less from the single as compared to the combination gel (0.4331 μg/cm(2)/min(1/2)). Titrations of the gels showed 10-fold more drug was needed to protect ectocervical than colonic tissue. The combination gel showed ~10- and 100-fold improved activity as compared to DPV and MVC gel, respectively. All gels were safe. CONCLUSIONS: The DPV/MVC gel showed a benefit blocking HIV infection of mucosal tissue compared to the single entity gels. Combination products with drugs affecting unique steps in the viral replication cycle would be advantageous for HIV prevention.
Entities:
Keywords:
Antiretroviral drugs; Drug combinations; HIV prevention; Pre-exposure prophylaxis; Rectal microbicides
Authors: Sheila R Abner; Patricia C Guenthner; Jeannette Guarner; Kelly A Hancock; James E Cummins; Aaron Fink; G Thomas Gilmore; Charles Staley; Albert Ward; Odessa Ali; Sander Binderow; Stephen Cohen; Lisa A Grohskopf; Lynn Paxton; Clyde E Hart; Charlene S Dezzutti Journal: J Infect Dis Date: 2005-09-26 Impact factor: 5.226
Authors: Annalene M Nel; Shanique C Smythe; Sepideh Habibi; Paulina E Kaptur; Joseph W Romano Journal: J Acquir Immune Defic Syndr Date: 2010-10 Impact factor: 3.731
Authors: Xiping Wei; Julie M Decker; Hongmei Liu; Zee Zhang; Ramin B Arani; J Michael Kilby; Michael S Saag; Xiaoyun Wu; George M Shaw; John C Kappes Journal: Antimicrob Agents Chemother Date: 2002-06 Impact factor: 5.191
Authors: Michael C Thigpen; Poloko M Kebaabetswe; Lynn A Paxton; Dawn K Smith; Charles E Rose; Tebogo M Segolodi; Faith L Henderson; Sonal R Pathak; Fatma A Soud; Kata L Chillag; Rodreck Mutanhaurwa; Lovemore Ian Chirwa; Michael Kasonde; Daniel Abebe; Evans Buliva; Roman J Gvetadze; Sandra Johnson; Thom Sukalac; Vasavi T Thomas; Clyde Hart; Jeffrey A Johnson; C Kevin Malotte; Craig W Hendrix; John T Brooks Journal: N Engl J Med Date: 2012-07-11 Impact factor: 91.245
Authors: Jared M Baeten; Deborah Donnell; Patrick Ndase; Nelly R Mugo; James D Campbell; Jonathan Wangisi; Jordan W Tappero; Elizabeth A Bukusi; Craig R Cohen; Elly Katabira; Allan Ronald; Elioda Tumwesigye; Edwin Were; Kenneth H Fife; James Kiarie; Carey Farquhar; Grace John-Stewart; Aloysious Kakia; Josephine Odoyo; Akasiima Mucunguzi; Edith Nakku-Joloba; Rogers Twesigye; Kenneth Ngure; Cosmas Apaka; Harrison Tamooh; Fridah Gabona; Andrew Mujugira; Dana Panteleeff; Katherine K Thomas; Lara Kidoguchi; Meighan Krows; Jennifer Revall; Susan Morrison; Harald Haugen; Mira Emmanuel-Ogier; Lisa Ondrejcek; Robert W Coombs; Lisa Frenkel; Craig Hendrix; Namandjé N Bumpus; David Bangsberg; Jessica E Haberer; Wendy S Stevens; Jairam R Lingappa; Connie Celum Journal: N Engl J Med Date: 2012-07-11 Impact factor: 91.245
Authors: Charlene S Dezzutti; Laura J Else; Sarah E Yandura; Cory Shetler; Julie Russo; David J Back; Ian McGowan Journal: Antimicrob Agents Chemother Date: 2016-04-22 Impact factor: 5.191
Authors: Margaret O Ilomuanya; Ayotunde T Hameedat; Edidiong N Akang; Sabdat O Ekama; Boladale O Silva; Alani S Akanmu Journal: Futur J Pharm Sci Date: 2020-11-14
Authors: Beatrice A Chen; Jingyang Zhang; Holly M Gundacker; Craig W Hendrix; Craig J Hoesley; Robert A Salata; Charlene S Dezzutti; Ariane van der Straten; Wayne B Hall; Cindy E Jacobson; Sherri Johnson; Ian McGowan; Annalene M Nel; Lydia Soto-Torres; Mark A Marzinke Journal: Clin Infect Dis Date: 2019-03-19 Impact factor: 9.079